Early empiric antibiotic use in COVID-19 patients: results from the international VIRUS registry

Decorative image of the AMR Learning Lounge

Early empiric antibiotic use in COVID-19 patients: results from the international VIRUS registry

SUMMARY

International Journal of Infectious Diseases | December 19, 2023

With the increased demand for hospitalization that COVID-19 generated around the world, came the escalation of inappropriate antibiotic use.

Results from the Society of Critical Care Medicine Discovery VIRUS international COVID-19 Registry aim to determine the rate and factors associated with early empiric antibiotic (EEAB) treatment to help set goals for antimicrobial stewardship efforts, in the post-pandemic era.

Featured Experts

Uluhan Sili MD, PhD, Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Türkiye

Aysun Tekin MD, Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

Huseyin Bilgin MD, MPH, Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Marmara University, Istanbul, Türkiye et al

GET STARTED

Read more about this important research ➡

Learn More!

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

GLOBAL Solutions

BIOFIRE^® SPOTFIRE^® Respiratory Panels

Point-of-care respiratory testing solutions with SPOTFIRE Respiratory Panels offering rapid syndromic PCR tests for a range of common pathogens.

Learn More

US Solutions

Diagnose respiratory pathogens quickly and accurately with the BioFire® Respiratory 2.1 (RP2.1) Panel

SARS-CoV-2 is a top concern for patients and clinicians, but several respiratory pathogens can cause nearly indistinguishable symptoms. The FDA De Novo authorized BioFire RP2.1 Panel is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.

Learn More

PUBLISHED ON

May 6, 2024